Summary
Written by a model from the transcript; not yet reviewed.
This episode explores the history, science, and public controversy surrounding statins, the wonder drugs that revolutionized cholesterol management. The hosts trace Akira Endo's serendipitous discovery of the first statin from fungi in the 1970s through the landmark 1980s clinical trials that finally connected cholesterol-lowering interventions to reduced cardiovascular events. They explain how statins inhibit HMG-CoA reductase in the liver to drastically cut LDL cholesterol production and upregulate LDL receptors, while detailing alternative therapies like ezetimibe and PCSK9 inhibitors. The conversation addresses why millions of patients discontinue statins due to side effects, mistrust, and widespread misinformation, emphasizing that decades of rigorous global data confirm these drugs save millions of lives by preventing heart attacks and strokes.
- Statins lower cholesterol by blocking HMG-CoA reductase, the rate-limiting enzyme required for cholesterol synthesis in the liver. 47:42
- Dietary changes and lifestyle modifications are essential first-line treatments, but genetics often play a dominant role in determining cholesterol levels. 1:13:30
- Large-scale clinical trials and meta-analyses confirm that statins safely reduce LDL cholesterol and significantly lower cardiovascular event risks. 1:16:00
- Muscle aches are a frequently cited side effect of statins, but studies suggest the vast majority are not directly caused by the drug. 54:21
Chapters
- 0:01Podcast Intro and Advertisements
The episode opens with a series of product advertisements and a brief host introduction before transitioning to the main topic.
- 12:30Introduction to Statins and Host Overview
Hosts Erin Welsh and Erin Allman Updike set the stage for the episode, previewing the history and impact of statins.
- 17:46Clinical Trials and Regulatory Milestones
Discussion of the 1983 cholesterol‑lowering trial, NIH consensus conferences, and the approval of the first statins in the 1980s.
- 22:10Historical Development of Statins
The narrative traces the discovery of statins by Akira Endo, the early research, and the first clinical trials that proved their efficacy.
- 26:22Controversies and Public Perception
Exploration of the reasons people avoid or discontinue statins, including side‑effect fears, mistrust, and misinformation.
- 56:17Statin Side Effects and Meta‑Analysis
The hosts examine the percentage of side effects attributable to statins and discuss the challenges of distinguishing true drug effects from placebo or aging.
- 56:57Balancing Population vs Individual Risk
They explore how population‑level data on statin benefits differ from individual risk calculations and the difficulty of managing side effects.
- 58:55Building Trust with Physicians
The conversation turns to the importance of a trusted healthcare provider in navigating statin therapy and side effect concerns.
- 59:55Alternative Lipid‑Lowering Drugs
They discuss ezetimibe and PCSK9 inhibitors, explaining their mechanisms and effectiveness compared to statins.
- 1:00:38PCSK9 Inhibitors Explained
A detailed explanation of how PCSK9 inhibitors work, including the Velcro glove analogy and the types of drugs available.
- 1:03:54Side Effects and Cost of PCSK9 Therapies
The hosts address the limited data on side effects, high costs, and the lack of long‑term evidence for newer lipid‑lowering agents.
- 1:06:00Long‑Term Management of Atherosclerosis
The discussion highlights the chronic nature of atherosclerosis, the need for lifelong therapy, and the challenges of patient adherence.
Highlights
- 12:39
1983 Statin Skepticism Among Doctorsdata
A 1983 survey revealed that half of US internists would not recommend any therapy for cholesterol unless levels exceeded 300, highlighting how recently medical consensus on cholesterol was established.
- 19:54
Discovering Statins From Mold Fungistory
Biochemist Akira Endo reasoned that just as fungi produce antibacterial compounds to compete, they might also produce compounds that interfere with cholesterol, leading him to screen 6,000 microbial strains.
- 22:49
Pharmaceutical Companies Screening Fungistory
Inspired by Endo's work, Merck researchers screened only 18 fungal strains before discovering their own statin, Lovastatin, in 1978.
- 33:48
The Nocebo Effect and Muscle Achesinsight
Double-blind studies show that patients taking placebos experience muscle aches at rates similar to statin groups, indicating anticipation of side effects plays a major role.
- 51:55
Statin Intensity and LDL Reductionstrategy
Statins vary in potency; high-intensity regimens lower LDL cholesterol by at least 50 percent, whereas low-intensity regimens reduce it by less than 30 percent.
- 1:00:44
How PCSK9 Inhibitors Recycle Receptorsinsight
PCSK9 proteins normally degrade LDL receptors, so blocking them allows more receptors to remain on cell surfaces and vacuum LDL cholesterol from the bloodstream.
- 1:12:45
Preventing One Million Events in USdata
Estimates suggest that ensuring every eligible patient in the US takes a statin could prevent one million cardiovascular disease events over ten years.
Quotes
“The first hit on this was less of a needle and more of a crochet hook.”
Unnamed speaker · 22:01 “Statins look to be the next blockbuster drug.”
Unnamed speaker · 24:00 “In 1971, the firsthand account provider for this episode, Dr. Akira Endo, was working as a research biochemist at the Japanese pharmaceutical company, Sankeo, when he got an idea.”
Unnamed speaker · 19:54 “Statins block an enzyme in our liver that's called HMG-CoA reductase.”
Unnamed speaker · 47:42 “The nocebo effect is the opposite of the placebo effect.”
Unnamed speaker · 33:56 “I don't know. I don't, we don't have an answer to that.”
Unnamed speaker · 56:33 “It's really, really tricky because it's not that these symptoms are not real, right? And, and if you are one of those people who has that severe side effect, right, one of four per 10,000, that's a very real effect for you.”
Unnamed speaker · 57:18 “PCSK9 is the shorthand name for a protein that I'm not gonna tell you the name of because I don't know it, it's too long. But this is a protein that our liver makes. It's really interesting. Its job, this protein, is to degrade, break down LDL receptor proteins.”
Unnamed speaker · 1:00:39
Sponsored segments
- Lincoln Rejuvenate 0:01–0:35
- Clinique Moisture Surge 100 Hour 1:09–1:39
- thispodcastwillkillyou.com 6:31–6:37
- thispodcastwillkillyou.com 6:49–6:55
- bookshop.org 7:03–7:11
- Vagisil 8:07–8:33
- Quince 8:44–9:54
- Patreon 1:17:20–1:17:28
- Jamie Foxx 1:18:03–1:18:24
- Clinique 1:18:36–1:18:59
About this episode
Last week, we set the stage by breaking down the science behind cholesterol: how it moves through our body, why it causes disease, and when we discovered the link between LDL and atherosclerosis. This week, armed with that knowledge, we’re asking the big question: what do we do about high cholesterol? Statins emerged as a highly effective intervention but one that is not without its share of controversy and misinformation. We delve into the story and science of statins and other cholesterol-lowering drugs, from their brilliant discovery to early promising trials, from barriers preventing their use to the heaps of misinformation abounding on the internet. How do statins actually work? What does penicillin have to do with their discovery? What’s the deal with side effects? Tune in for all this and more. Support this podcast by shopping our latest sponsor deals and promotions at this link: https://bit.ly/3WwtIAu See omnystudio.com/listener https://omnystudio.com/listener for privacy information.
Transcript
12,667 words · 14 speakers
Topics
- statins
- cardiovascular disease
- LDL cholesterol
- HMG-CoA reductase
- PCSK9 inhibitors
- phytosterols
- red yeast rice
- ezetimibe
- atherosclerosis
- JAMA
Page updated · transcript and summary are machine-generated